These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18278833)

  • 1. The percentage of patients with seronegative spondyloarthritis requiring magnetic resonance imaging to meet the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada guidelines for access to anti-tumor necrosis factor treatment.
    Troppmann L; Karsh J;
    J Rheumatol; 2008 Apr; 35(4):658-61. PubMed ID: 18278833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
    Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
    J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
    Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis.
    Maksymowych WP; Inman RD; Salonen D; Dhillon SS; Williams M; Stone M; Conner-Spady B; Palsat J; Lambert RG
    Arthritis Rheum; 2005 Oct; 53(5):703-9. PubMed ID: 16208659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis.
    Maksymowych WP; Inman RD; Salonen D; Dhillon SS; Krishnananthan R; Stone M; Conner-Spady B; Palsat J; Lambert RG
    Arthritis Rheum; 2005 Aug; 53(4):502-9. PubMed ID: 16082639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.
    Rudwaleit M; Baraliakos X; Listing J; Brandt J; Sieper J; Braun J
    Ann Rheum Dis; 2005 Sep; 64(9):1305-10. PubMed ID: 15778243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment.
    Lukas C; Braun J; van der Heijde D; Hermann KG; Rudwaleit M; Østergaard M; Oostveen A; O'Connor P; Maksymowych WP; Lambert RG; Jurik AG; Baraliakos X; Landewé R;
    J Rheumatol; 2007 Apr; 34(4):862-70. PubMed ID: 17407241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis.
    Weber U; Maksymowych WP; Jurik AG; Pfirrmann CW; Rufibach K; Kissling RO; Khan MA; Lambert RG; Hodler J
    Arthritis Rheum; 2009 Jul; 61(7):893-9. PubMed ID: 19565546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of active spinal inflammatory changes in patients with axial spondyloarthritis: validation of whole body MRI against conventional MRI.
    Weber U; Hodler J; Jurik AG; Pfirrmann CW; Rufibach K; Kissling RO; Khan MA; Lambert RG; Maksymowych WP
    Ann Rheum Dis; 2010 Apr; 69(4):648-53. PubMed ID: 19416801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study.
    Collantes-Estevez E; Muñoz-Villanueva MC; Zarco P; Torre-Alonso JC; Gratacós J; González C; Sanmartí R; Cañete JD;
    Rheumatology (Oxford); 2005 Dec; 44(12):1555-8. PubMed ID: 16118228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial.
    Mok CC; Li OC; Chan KL; Ho LY; Hui PK
    Scand J Rheumatol; 2015; 44(6):480-6. PubMed ID: 26271141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study.
    Tan AL; Marzo-Ortega H; O'Connor P; Fraser A; Emery P; McGonagle D
    Ann Rheum Dis; 2004 Sep; 63(9):1041-5. PubMed ID: 15066864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term changes in magnetic resonance imaging and disease activity in response to infliximab.
    Bonel HM; Boller C; Saar B; Tanner S; Srivastav S; Villiger PM
    Ann Rheum Dis; 2010 Jan; 69(1):120-5. PubMed ID: 19329424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.